Latest Rember Stories

PHILADELPHIA and LONDON, Nov. 12, 2012 /PRNewswire/ -- MediciGlobal Inc., announced today that over 25,000 fans have shown their support for clinical research by joining the Facebook page Alzheimer's Team. The community supports research efforts into clinical research aimed at halting the progression of mild to moderate Alzheimer's disease. "We are the first Facebook community to inform people about the role of Tau tangles in Alzheimer's disease, and the development of the first...

MONTE CARLO, Monaco, October 30, 2012 /PRNewswire/ -- The time for Tau is now as Phase 3 clinical trials get under way with a second-generation Tau Aggregation Inhibitor (TAI) aimed at halting the progression of Alzheimer's TauRx Therapeutics Ltd announced today the initiation of two global Phase 3 clinical trials in mild to moderate Alzheimer's disease. These landmark studies could provide the first definitive data on a...

MANCHESTER, England, September 10, 2012 /PRNewswire/ -- Investigational drug study follows earlier study with promising results in mild to moderate Alzheimer's patients TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held...

Laboratory study shows drug targets chaperone Hsp70 to reduce Alzheimer's proteinInhibiting the protein Hsp70 rapidly reduces brain levels of tau, a protein associated with Alzheimer's disease when it builds up abnormally inside nerve cells affecting memory, neuroscientists at the University of South Florida found. The study is reported online Sept. 29 in the Journal of Neuroscience."Now that we've discovered that targeting the chaperone protein Hsp70 can clear tau, it could be helpful...

By Donovan, Paul Dementia "Hi, mate, how are you?" is a greeting that has come to haunt me. It came from my dad on a recent visit to the care home where he lives, offering a glimpse of what he used to be like. Dad suffers with dementia. When the family visits he sits, occasionally acknowledging us, but usually just fiddling with things. At his worst, he appears to be in a sort of torment. News that the University of Aberdeen has developed Rember, a drug that can slow the progression of...

SCOTS scientists have developed a drug they say can halt the devastating progress of Alzheimer's disease. It could prove at least twice as effective in treating the disease as current medicines. The drug, known as rember, slows progression of the disease by as much as 81per cent. People taking it for 50 weeks had a slower decline in blood flow to the parts of the brain that are important for memory than those taking a dummy pill. Rember is the first drug to act on the 'tangles' that...

By DOMINIC JEFF Herald Reporter Alzheimer's support workers in Plymouth have cautiously welcomed news of a new drug which may halt the progression of the disease. Trials of the drug Rember by Aberdeen University researchers showed an 81 per cent difference in the rate of mental decline among those taking the treatment. Ian Sherriff, chairman of the Plymouth and district branch of the Alzheimer's Society, said: "It's good news. It's clearly still in a testing stage, but the figures I've...

By CHRIS THORNTON A NEW drug hailed as a potential breakthrough in the fight against Alzheimer's is still years away from being available in Northern Ireland, an MP whose husband suffers from the disease has warned. Lady Sylvia Hermon said revelations this week about trials of the drug Rember - which has slowed the disease remarkably in a clinical trial - are "truly encouraging". But she said "the major prize" of preventing the killer disease is still elusive. Lady Sylvia has spoken...

A NEW drug could prove at least twice as effective in treating Alzheimer's disease as current medicines, research has shown. The drug, rember, slows progression of the disease by as much as 81%, a British-led study found. People taking it for 50 weeks had a slower decline in blood flow to the parts of the brain that are important for memory than those taking a dummy pill. Rember acts on the tau tangles that develop in the brains of Alzheimer's sufferers. Made up of the protein tau,...

By Jeremy Manier, Chicago Tribune Jul. 31--Editor's note: Due to a production error, this story from Wednesday's newspaper did not run in full. This is the complete text. Hope is often scarce in research on Alzheimer's disease, but a study released Tuesday at a Chicago medical conference offered tentative hope for a new way of slowing elderly patients' mental decline. The preliminary study of 321 Alzheimer's patients from Singapore and Britain found that an old drug, previously used...